Richard Newcomb Stillwell - 15 Mar 2023 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Director
Signature
/s/ Jessica Morris as attorney-in-fact
Issuer symbol
TNXP
Transactions as of
15 Mar 2023
Net transactions value
$0
Form type
4
Filing time
16 Mar 2023, 19:43:34 UTC
Next filing
10 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +83,000 $0.000000 83,000 15 Mar 2023 Common Stock 83,000 $0.5620 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.
F2 This option vests on the Issuer's 2023 Annual Meeting of Stockholders.